Association of serum lipids with macular thickness and volume in type 2 diabetes without diabetic macular edema

Investigative Ophthalmology and Visual Science

Volumn 55, Issue 3, 2014, Pages 1749-1753

  Sasaki, Mariko ^a,b   Kawashima, Motoko ^a   Kawasaki, Ryo ^b,c   Uchida, Atsuro ^a   Koto, Takashi ^a   Shinoda, Hajime ^a   Tsubota, Kazuo ^a   Wang, Jie Jin ^b,d   Ozawa, Yoko ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c YAMAGATA UNIVERSITY   (Japan)

^d WESTMEAD HOSPITAL   (Australia)

Author keywords

Diabetes; Diabetic macular edema; Macular edema; Macular thickness; Optical coherence tomography

Indexed keywords

HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ANTHROPOMETRIC PARAMETERS; ARTICLE; BLOOD PRESSURE MONITORING; BODY MASS; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; FEMALE; HUMAN; LIPID BLOOD LEVEL; MACULAR THICKNESS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RISK FACTOR; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY;

DIABETES; DIABETIC MACULAR EDEMA; MACULAR EDEMA; MACULAR THICKNESS; OPTICAL COHERENCE TOMOGRAPHY;

DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; LIPIDS; MACULA LUTEA; MACULAR EDEMA; MALE; MIDDLE AGED; ORGAN SIZE; RETROSPECTIVE STUDIES; RISK FACTORS; TOMOGRAPHY, OPTICAL COHERENCE;

EID: 84897895687     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.13-13035     Document Type: Article

References (37)

1. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology. 1991;98:766-785.
2. Lardenoye CW, Probst K, DeLint PJ, Rothova A. Photoreceptor function in eyes with macular edema. Invest Ophthalmol Vis Sci. 2000;41:4048-4053.
3. Joussen AM, Smyth N, Niessen C. Pathophysiology of diabetic macular edema. Dev Ophthalmol. 2007;39:1-12.
4. Yau JW, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012; 35:556-564.
5. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema. Ophthalmology. 1984;91:1464-1474.
6. Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XV. The longterm incidence of macular edema. Ophthalmology. 1995;102: 7-16.
7. Klein BE, Moss SE, Klein R, Surawicz TS. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XIII. Relationship of serum cholesterol to retinopathy and hard exudate. Ophthalmology. 1991;98:1261-1265.
8. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol. 1985;103:1796-1806.
9. Lopes de Faria JM, Jalkh AE, Trempe CL, McMeel JW. Diabetic macular edema: risk factors and concomitants. Acta Ophthalmol Scand. 1999;77:170-175.
10. Matthews DR, Stratton IM, Aldington SJ, Holman RR, Kohner EM. Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus: UKPDS 69. Arch Ophthalmol. 2004;122:1631-1640.
11. Miljanovic B, Glynn RJ, Nathan DM, Manson JE, Schaumberg DA. A prospective study of serum lipids and risk of diabetic macular edema in type 1 diabetes. Diabetes. 2004;53:2883-2892.
12. Rema M, Srivastava BK, Anitha B, Deepa R, Mohan V. Association of serum lipids with diabetic retinopathy in urban South Indians-the Chennai Urban Rural Epidemiology Study (CURES) Eye Study-2. Diabet Med. 2006;23:1029-1036.
13. Raman R, Rani PK, Kulothungan V, Rachepalle SR, Kumaramanickavel G, Sharma T. Influence of serum lipids on clinically significant versus nonclinically significant macular edema: SN-DREAMS Report number 13. Ophthalmology. 2010;117:766-772.
14. Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BE. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XXII the twenty-five-year progression of retinopathy in persons with type 1 diabetes. Ophthalmology. 2008;115:1859-1868.
15. Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BE. The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXIII: the twenty-five-year incidence of macular edema in persons with type 1 diabetes. Ophthalmology. 2009;116:497-503.
16. Benarous R, Sasongko MB, Qureshi S, et al. Differential association of serum lipids with diabetic retinopathy and diabetic macular edema. Invest Ophthalmol Vis Sci. 2011;52: 7464-7469.
17. Bhavsar KV, Subramanian ML. Risk factors for progression of subclinical diabetic macular oedema. Br J Ophthalmol. 2011; 95:671-674.
18. Massin P, Bandello F, Garweg JG, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care. 2010;33:2399-2405.
19. Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118:615-625.
20. Nguyen QD, Shah SM, Khwaja AA, et al. Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. Ophthalmology. 2010;117:2146-2151.
21. Scott IU, Edwards AR, Beck RW, et al. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology. 2007;114:1860-1867.
22. Elman MJ, Aiello LP, Beck RW, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010;117:1064-1077, e1035.
23. Elman MJ, Bressler NM, Qin H, et al. Expanded 2-year followup of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2011;118:609-614.
24. Chalam KV, Bressler SB, Edwards AR, et al. Retinal thickness in people with diabetes and minimal or no diabetic retinopathy: Heidelberg Spectralis optical coherence tomography. Invest Ophthalmol Vis Sci. 2012;53:8154-8161.
25. Ikeda N, Iijima R, Hara H, Moroi M, Nakamura M, Sugi K. Glycated hemoglobin is associated with the complexity of coronary artery disease, even in non-diabetic adults. J Atheroscler Thromb. 2012;19:1066-1072.
26. Chew EY, Klein ML, Ferris FL III, et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Arch Ophthalmol. 1996;114:1079-1084.
27. Idiculla J, Nithyanandam S, Joseph M, Mohan VA, Vasu U, Sadiq M. Serum lipids and diabetic retinopathy: a cross-sectional study. Indian J Endocrinol Metab. 2012;16:S492-S494.
28. Sasaki M, Ozawa Y, Kurihara T, et al. Neurodegenerative influence of oxidative stress in the retina of a murine model of diabetes. Diabetologia. 2010;53:971-979.
29. Sasaki M, Kawasaki R, Noonan JE, Wong TY, Lamoureux EL, Wang JJ. Quantitative measurement of hard exudates in patients with diabetes and their associations with serum lipid levels. Invest Ophthalmol Vis Sci. 2013;54:5544-5550.
30. Keech AC, Mitchell P, Summanen PA, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet. 2007;370:1687-1697.
31. Nagaoka T, Takahashi A, Sato E, et al. Effect of systemic administration of simvastatin on retinal circulation. Arch Ophthalmol. 2006;124:665-670.
32. Sasaki M, Gan WL, Kawasaki R, et al. Effect of simvastatin on retinal vascular caliber: the Age-Related Maculopathy Statin Study. Acta Ophthalmol. 2013;91:e418-e419.
33. Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebocontrolled trial. Lancet. 2003;361:2005-2016.
34. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364:685-696.
35. Bressler NM, Miller KM, Beck RW, et al. Observational study of subclinical diabetic macular edema. Eye (Lond). 2012;26:833-840.
36. Bressler NM, Edwards AR, Antoszyk AN, et al. Retinal thickness on Stratus optical coherence tomography in people with diabetes and minimal or no diabetic retinopathy. Am J Ophthalmol. 2008;145:894-901.
37. Dhamdhere KP, Bearse MA Jr, Harrison W, Barez S, Schneck ME, Adams AJ. Associations between local retinal thickness and function in early diabetes. Invest Ophthalmol Vis Sci. 2012;53:6122-6128.